According to BlueWillow Biologics, the University of Michigan has been issued US patent No. 10,138,279 which covers an intranasal anthrax vaccine formulated with BlueWillow’s NanoVax adjuvant. BlueWillow (formerly NanoBio) is a spin out from the University of Michigan and has an exclusive license to the anthrax vaccine.
The company said that its partner Porton Biopharma Limited (PBL) expects to initiate Phase 1 studies of the NanoVax anthrax vaccine later this year and that multiple pre-clinical studies have demonstrated immunogenicity and protection against anthrax in animal models.
BlueWillow is also developing intranasal vaccines using NanoVax for chlamidia, herpes simplex virus 2 (HSV-2), influenza, pertussis, and respiratory syncytial virus (RSV).
Read the BlueWillow Biologics press release.
